Prestige Consumer Healthcare (PBH) Liabilities and Shareholders Equity (2011 - 2025)
Prestige Consumer Healthcare (PBH) recorded quarterly Liabilities and Shareholders Equity of $3.5 billion in Q4 2025, up 1.52% quarter-over-quarter from $3.4 billion in Q3 2025, and up 4.96% on a YoY basis from $3.3 billion in Q4 2024.
Prestige Consumer Healthcare (PBH) Liabilities and Shareholders Equity (2011 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $3.5 billion for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 4.96% year-over-year to $3.5 billion; the TTM figure through Dec 2025 stood at $13.8 billion (up 3.76% YoY), while the FY2025 annual figure was $3.4 billion, up 2.53% from the prior year.
- Liabilities and Shareholders Equity was $3.5 billion for Q4 2025 at Prestige Consumer Healthcare, up from $3.4 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.7 billion in Q4 2022 to a low of $3.3 billion in Q2 2024.
- Historically, Liabilities and Shareholders Equity has averaged $3.5 billion across 5 years, with a median of $3.4 billion in 2021.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity rose 7.04% in 2022, then declined 10.93% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.7 billion in 2021, then increased by 2.47% to $3.7 billion in 2022, then dropped by 10.93% to $3.3 billion in 2023, then decreased by 0.31% to $3.3 billion in 2024, then gained by 4.96% to $3.5 billion in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $3.5 billion (Q4 2025), $3.4 billion (Q3 2025), and $3.4 billion (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 2.35 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 2.27 Bn |
| 10 | Prestige Consumer Healthcare | 2.33 Bn | 2.26 Bn | 157.37 Mn | 3.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.49 Bn |
| Sep 30, 2025 | 3.44 Bn |
| Jun 30, 2025 | 3.43 Bn |
| Mar 31, 2025 | 3.40 Bn |
| Dec 31, 2024 | 3.33 Bn |
| Sep 30, 2024 | 3.32 Bn |
| Jun 30, 2024 | 3.31 Bn |
| Mar 31, 2024 | 3.32 Bn |
| Dec 31, 2023 | 3.34 Bn |
| Sep 30, 2023 | 3.33 Bn |
| Jun 30, 2023 | 3.35 Bn |
| Mar 31, 2023 | 3.35 Bn |
| Dec 31, 2022 | 3.75 Bn |
| Sep 30, 2022 | 3.68 Bn |
| Jun 30, 2022 | 3.68 Bn |
| Mar 31, 2022 | 3.67 Bn |
| Dec 31, 2021 | 3.66 Bn |
| Sep 30, 2021 | 3.68 Bn |
| Jun 30, 2021 | 3.56 Bn |
| Mar 31, 2021 | 3.43 Bn |